Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (12)

2024

  1. Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antivirals

    AIDS reviews, Vol. 25, Núm. 4, pp. 162-172

2023

  1. Rebound in sexually transmitted infections after the COVID-19 pandemic

    AIDS reviews, Vol. 26, Núm. 3, pp. 127-135

2020

  1. Hospital admissions in individuals with HTLV-1 infection in Spain

    AIDS, Vol. 34, Núm. 7, pp. 1019-1027

2019

  1. HTLV-1 infection in solid organ transplant donors and recipients in Spain

    BMC Infectious Diseases, Vol. 19, Núm. 1

2018

  1. Decline and changing profile of hepatitis delta among injection drug users in Spain

    Antiviral Therapy, Vol. 23, Núm. 1, pp. 87-90

2017

  1. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  2. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

2014

  1. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  2. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2007

  1. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients

    Journal of Viral Hepatitis, Vol. 14, Núm. 6, pp. 387-391

2005

  1. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C

    Antiviral Therapy, Vol. 10, Núm. 5, pp. 657-662